Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tigecycline.

James E Frampton1, Monique P Curran

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|January 6, 2006
PubMed
Summary
This summary is machine-generated.

Tigecycline, a novel glycylcycline antibiotic, effectively treats complicated skin and complicated intra-abdominal infections by overcoming tetracycline resistance. Clinical trials confirm its non-inferiority to standard therapies, demonstrating its efficacy and tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Pemigatinib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024
Same author

Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2023
Same author

Epcoritamab: First Approval.

Drugs·2023
Same author

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023
Same author

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Tigecycline represents a new class of broad-spectrum antibiotics, glycylcyclines.
  • It was developed to combat tetracycline resistance mechanisms like ribosomal protection and efflux.
  • Tigecycline exhibits in vitro activity against Gram-positive and Gram-negative bacteria relevant to cSSSIs and cIAIs.

Purpose of the Study:

  • To evaluate the efficacy and safety of tigecycline for treating complicated skin and skin structure infections (cSSSIs).
  • To assess the efficacy and safety of tigecycline for treating complicated intra-abdominal infections (cIAIs).

Main Methods:

  • Pivotal Phase III clinical trials were conducted in hospitalized adult patients.
  • Tigecycline monotherapy was compared against combination therapy (vancomycin plus aztreonam) for cSSSIs.

Related Experiment Videos

  • Tigecycline monotherapy was compared against broad-spectrum therapy (imipenem/cilastatin) for cIAIs.

    • Main Results:

    • Tigecycline monotherapy demonstrated non-inferiority to vancomycin plus aztreonam for cSSSIs (pooled cure rates: 86.5% vs 88.6%).
    • Tigecycline monotherapy showed non-inferiority to imipenem/cilastatin for cIAIs (pooled cure rates: 86.1% vs 86.2%).
    • The most common adverse events were nausea, vomiting, and diarrhea, consistent across treatment groups.

    Conclusions:

    • Tigecycline is an effective monotherapy for cSSSIs and cIAIs in adults.
    • The safety profile of tigecycline is comparable to established treatments.
    • Tigecycline offers a valuable therapeutic option against resistant bacteria in these infection types.